Click here to read some interesting recently published papers from our community. If you have published an article in the field of in silico medicine, send it to us: we will include it in this section of the newsletter!
A vision: in silico clinical trials without patients
Lesley A.Ogilvie et al
Abstract
The development of the technology required to generate (molecular) digital twins provides the technological basis for in silico clinical trials, as well as major virtualization of many other steps in the drug development process, offering the potential of orders of magnitude reductions in the cost of bringing new drugs to the market, and a corresponding increase in new drugs in many disease areas, including those for which risks have been considered too high to justify commercial development. The same basic technology will, however, also be used to truly personalize therapy choice and preventive and wellness measures, further increasing health and well-being worldwide.
----------------------------------------------------------------------------
Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study
Soren Sabet Sarvestany et al
Abstract
Cirrhosis is the result of advanced scarring (or fibrosis) of the liver, and is often diagnosed once decompensation with associated complications has occurred. Current non-invasive tests to detect advanced liver fibrosis have limited performance, with many indeterminate classifications. We aimed to identify patients with advanced liver fibrosis of all-causes using machine learning algorithms (MLAs).
